655 Combination of cysteamine and isobionic-amide in a new formulation to decrease epidermal pigmentation

Hyperpigmentation disorders are characterized by an overproduction of melanin. Treatments for pigmentary either disrupt the biosynthesis melanin or cytotoxic to melanocyte. Cysteamine a well-studied depigmenting agent inhibits synthesis at several steps in melanogenesis pathway. It is now through development novel complex combining stabilized cysteamine (st. Cys) with isobionic-amide, forming new technology that results more efficacious skin activity. Isobionic-amide part vitamin B3 family blocking transfer melanosomes into keratinocytes. Our vitro studies have shown isobionic-amide be non-cytotoxic and potent than agent, niacinamide. The combined activities st.Cys may offer novel, safe, approach inhibition melanosomal resulting reduction Cell culture were conducted comparing niacinamide evaluate cellular viability, inhibition. Melanocytotoxicity was only seen very high concentrations (500 μm) compared B16 cells. In BDVII cells, keratinocytotoxicity observed concentration 200 μm Niacinamide. significantly reduced from melanocytes keratinocytes our model. non-toxic ingredient targeting melanosome depigmentation coupled increase pigment correction.